LXRX
Lexicon Pharmaceuticals, Inc.
Price Chart
Latest Quote
$2.22
+0.06 (+2.78%)
Current Price
| Previous Close | $2.16 |
| Open | $2.19 |
| Day High | $2.27 |
| Day Low | $2.18 |
| Volume | 2,818,084 |
Stock Information
| Shares Outstanding | 444.20M |
| Total Debt | $57.71M |
| Cash Equivalents | $170.66M |
| Revenue | $69.64M |
| Net Income | $-26.09M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $986.12M |
| EPS (TTM) | $-0.07 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $873.17M |
| Sales | $69.64M |
| Income | $-26.09M |
| Book/sh | $0.48 |
| Cash/sh | $0.38 |
| Employees | 81 |
Financial Ratios
| Quick Ratio | 18.43 |
| Current Ratio | 18.80 |
| Debt/Eq | 28.45 |
Returns & Margins
| ROA | -5.35% |
| ROE | -16.01% |
| Gross Margin | 94.12% |
| Operating Margin | -4.72% |
| Profit Margin | -37.46% |
Ownership
| Insider Ownership | 1.12% |
| Institutional Ownership | 78.73% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -10.76 |
| PEG | -13.77 |
| P/S | 14.16 |
| P/B | 4.63 |
Analyst Data
| Recommendation | buy |
| Target Price | $3.77 |
Technical Indicators
| SMA20 | $2.01 |
| SMA50 | $1.95 |
| SMA200 | $1.54 |
| RSI | 86.27 |
| ATR | 0.1164 |
| Shares Float | 262.53M |
| Short Float | 11.13% |
| Short Ratio | 8.65 |
| Volatility | 1.07 |
| Rel Volume | 1.26 |
Performance History
| Week | +13.85% |
| Month | +2.78% |
| Quarter | +29.07% |
| 6 Months | +89.74% |
| YTD | +94.74% |
| Year | +204.11% |
| 3 Years | -8.26% |
| 5 Years | -53.65% |
| 10 Years | -83.11% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $2.22 | 2,822,400 |
| 2026-06-23 | $2.16 | 2,774,100 |
| 2026-06-22 | $2.15 | 3,035,700 |
| 2026-06-18 | $2.01 | 3,927,200 |
| 2026-06-17 | $2.04 | 2,622,400 |
| 2026-06-16 | $1.95 | 1,853,900 |
| 2026-06-15 | $1.96 | 2,081,600 |
| 2026-06-12 | $1.92 | 2,994,300 |
| 2026-06-11 | $1.89 | 2,041,400 |
| 2026-06-10 | $1.88 | 1,283,100 |
| 2026-06-09 | $1.88 | 1,262,200 |
| 2026-06-08 | $1.88 | 1,489,300 |
| 2026-06-05 | $1.91 | 1,761,600 |
| 2026-06-04 | $1.90 | 1,756,800 |
| 2026-06-03 | $1.85 | 2,661,200 |
| 2026-06-02 | $1.89 | 3,157,400 |
| 2026-06-01 | $2.07 | 1,830,100 |
| 2026-05-29 | $2.18 | 1,617,900 |
| 2026-05-28 | $2.21 | 1,866,700 |
| 2026-05-27 | $2.17 | 1,931,000 |
| 2026-05-26 | $2.06 | 3,074,500 |
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
đ° Latest News
Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now?
Insider Monkey âĸ 2026-06-11T18:00:02Z
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
Motley Fool âĸ 2026-06-11T14:05:55Z
How The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst Updates
Simply Wall St. âĸ 2026-06-04T13:14:59Z
Lexicon (LXRX) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-06-01T20:40:21Z
Citi Raises its Price Target on Lexicon Pharmaceuticals (LXRX)
Insider Monkey âĸ 2026-05-22T18:43:11Z
Lexicon Pharmaceuticals (LXRX) Is Up 46.1% After Revenue Surges And Loss Narrows Sharply â What's Changed
Simply Wall St. âĸ 2026-05-13T06:13:05Z
Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk Milestones
Insider Monkey âĸ 2026-05-10T04:00:49Z
Lexicon Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-08T07:25:40Z
Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1
Zacks âĸ 2026-05-07T12:50:20Z
Novo Nordisk Extends Pipeline With Semaglutide Alcohol Study And LX9851 Trial
Simply Wall St. âĸ 2026-05-03T23:08:14Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $274,000 | $616,000 | $85,000 | $0 |
| Cost Of Revenue | $274,000 | $616,000 | $85,000 | $0 |
| Total Revenue | $49,803,000 | $31,081,000 | $1,204,000 | $139,000 |
| Operating Revenue | $49,803,000 | $31,081,000 | $1,204,000 | $139,000 |
| Expenses | ||||
| Interest Expense | $8,339,000 | $15,579,000 | $13,101,000 | $2,780,000 |
| Total Expenses | $98,714,000 | $228,198,000 | $172,954,000 | $100,899,000 |
| Net Non Operating Interest Income Expense | $-1,430,000 | $-3,286,000 | $-5,369,000 | $-1,184,000 |
| Interest Expense Non Operating | $8,339,000 | $15,579,000 | $13,101,000 | $2,780,000 |
| Operating Expense | $98,440,000 | $227,582,000 | $172,869,000 | $100,899,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-50,341,000 | $-200,403,000 | $-177,119,000 | $-101,944,000 |
| Net Interest Income | $-1,430,000 | $-3,286,000 | $-5,369,000 | $-1,184,000 |
| Interest Income | $6,909,000 | $12,293,000 | $7,732,000 | $1,596,000 |
| Normalized Income | $-50,341,000 | $-200,403,000 | $-177,119,000 | $-101,944,000 |
| Net Income From Continuing And Discontinued Operation | $-50,341,000 | $-200,403,000 | $-177,119,000 | $-101,944,000 |
| Total Operating Income As Reported | $-48,911,000 | $-197,117,000 | $-171,750,000 | $-100,760,000 |
| Net Income Common Stockholders | $-50,341,000 | $-200,403,000 | $-177,119,000 | $-101,944,000 |
| Net Income | $-50,341,000 | $-200,403,000 | $-177,119,000 | $-101,944,000 |
| Net Income Including Noncontrolling Interests | $-50,341,000 | $-200,403,000 | $-177,119,000 | $-101,944,000 |
| Net Income Continuous Operations | $-50,341,000 | $-200,403,000 | $-177,119,000 | $-101,944,000 |
| Pretax Income | $-50,341,000 | $-200,403,000 | $-177,119,000 | $-101,944,000 |
| Interest Income Non Operating | $6,909,000 | $12,293,000 | $7,732,000 | $1,596,000 |
| Operating Income | $-48,911,000 | $-197,117,000 | $-171,750,000 | $-100,760,000 |
| Gross Profit | $49,529,000 | $30,465,000 | $1,119,000 | $139,000 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-0.14 | $-0.63 | $-0.79 | $-0.62 |
| Basic EPS | $-0.14 | $-0.63 | $-0.79 | $-0.62 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-41,381,000 | $-184,290,000 | $-163,464,000 | $-98,737,000 |
| Reconciled Depreciation | $621,000 | $534,000 | $554,000 | $427,000 |
| EBITDA (Bullshit earnings) | $-41,381,000 | $-184,290,000 | $-163,464,000 | $-98,737,000 |
| EBIT | $-42,002,000 | $-184,824,000 | $-164,018,000 | $-99,164,000 |
| Diluted Average Shares | $363,053,000 | $320,031,000 | $221,130,000 | $165,733,000 |
| Basic Average Shares | $363,053,000 | $320,031,000 | $221,130,000 | $165,733,000 |
| Diluted NI Availto Com Stockholders | $-50,341,000 | $-200,403,000 | $-177,119,000 | $-101,944,000 |
| Research And Development | $61,121,000 | $84,480,000 | $58,887,000 | $52,816,000 |
| Selling General And Administration | $37,319,000 | $143,102,000 | $113,982,000 | $48,083,000 |
| Total Unusual Items | - | - | - | $0 |
| Total Unusual Items Excluding Goodwill | - | - | - | $0 |
| Gain On Sale Of Business | - | - | - | $0 |
| Impairment Of Capital Assets | - | - | - | $0 |
| Tax Provision | - | - | - | - |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $62,995,000 | $101,407,000 | $48,567,000 | $72,581,000 |
| Total Assets | $184,987,000 | $298,420,000 | $229,429,000 | $194,299,000 |
| Total Non Current Assets | $83,092,000 | $52,227,000 | $52,882,000 | $53,433,000 |
| Other Non Current Assets | $29,368,000 | $368,000 | $828,000 | $412,000 |
| Goodwill And Other Intangible Assets | $44,543,000 | $44,543,000 | $44,543,000 | $44,543,000 |
| Current Assets | $101,895,000 | $246,193,000 | $176,547,000 | $140,866,000 |
| Other Current Assets | $3,000,000 | $4,532,000 | $5,130,000 | $2,481,000 |
| Inventory | $281,000 | $231,000 | $381,000 | $0 |
| Receivables | $2,384,000 | $3,473,000 | $1,010,000 | $28,000 |
| Accounts Receivable | $2,384,000 | $3,473,000 | $1,010,000 | $28,000 |
| Cash Cash Equivalents And Short Term Investments | $96,230,000 | $237,957,000 | $170,026,000 | $138,357,000 |
| Cash And Cash Equivalents | $34,326,000 | $66,656,000 | $22,465,000 | $46,345,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $19,677,000 | $33,642,000 | $77,043,000 | $2,234,000 |
| Total Debt | $62,819,000 | $108,397,000 | $106,064,000 | $55,294,000 |
| Long Term Debt And Capital Lease Obligation | $56,582,000 | $107,222,000 | $104,773,000 | $54,003,000 |
| Long Term Debt | $49,408,000 | $100,298,000 | $99,508,000 | $48,579,000 |
| Current Debt And Capital Lease Obligation | $6,237,000 | $1,175,000 | $1,291,000 | $1,291,000 |
| Current Debt | $4,595,000 | - | - | - |
| Other Current Borrowings | $4,595,000 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $77,449,000 | $152,470,000 | $136,319,000 | $77,175,000 |
| Total Non Current Liabilities Net Minority Interest | $56,582,000 | $107,222,000 | $104,773,000 | $54,003,000 |
| Current Liabilities | $20,867,000 | $45,248,000 | $31,546,000 | $23,172,000 |
| Payables And Accrued Expenses | $8,215,000 | $29,361,000 | $20,664,000 | $14,051,000 |
| Payables | $3,083,000 | $14,801,000 | $14,389,000 | $10,395,000 |
| Accounts Payable | $3,083,000 | $14,801,000 | $14,389,000 | $10,395,000 |
| Equity | ||||
| Common Stock Equity | $107,538,000 | $145,950,000 | $93,110,000 | $117,124,000 |
| Total Equity Gross Minority Interest | $107,538,000 | $145,950,000 | $93,110,000 | $117,124,000 |
| Stockholders Equity | $107,538,000 | $145,950,000 | $93,110,000 | $117,124,000 |
| Gains Losses Not Affecting Retained Earnings | $30,000 | $119,000 | $31,000 | $-428,000 |
| Other Equity Adjustments | $30,000 | $119,000 | $31,000 | $-428,000 |
| Retained Earnings | $-2,017,583,000 | $-1,967,242,000 | $-1,766,839,000 | $-1,589,720,000 |
| Other | ||||
| Treasury Shares Number | $2,381,939 | $1,528,008 | $867,973 | $488,000 |
| Ordinary Shares Number | $363,466,277 | $361,492,295 | $244,924,695 | $188,726,000 |
| Share Issued | $365,848,216 | $363,020,303 | $245,792,668 | $189,214,000 |
| Tangible Book Value | $62,995,000 | $101,407,000 | $48,567,000 | $72,581,000 |
| Invested Capital | $161,541,000 | $246,248,000 | $192,618,000 | $165,703,000 |
| Working Capital | $81,028,000 | $200,945,000 | $145,001,000 | $117,694,000 |
| Capital Lease Obligations | $8,816,000 | $8,099,000 | $6,556,000 | $6,715,000 |
| Total Capitalization | $156,946,000 | $246,248,000 | $192,618,000 | $165,703,000 |
| Treasury Stock | $5,187,000 | $4,615,000 | $2,885,000 | $2,061,000 |
| Additional Paid In Capital | $2,129,912,000 | $2,117,325,000 | $1,862,558,000 | $1,709,144,000 |
| Capital Stock | $366,000 | $363,000 | $245,000 | $189,000 |
| Common Stock | $366,000 | $363,000 | $245,000 | $189,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $7,174,000 | $6,924,000 | $5,265,000 | $5,424,000 |
| Current Capital Lease Obligation | $1,642,000 | $1,175,000 | $1,291,000 | $1,291,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,415,000 | $14,712,000 | $9,591,000 | $7,830,000 |
| Current Accrued Expenses | $5,132,000 | $14,560,000 | $6,275,000 | $3,656,000 |
| Goodwill | $44,543,000 | $44,543,000 | $44,543,000 | $44,543,000 |
| Net PPE | $9,181,000 | $7,316,000 | $7,511,000 | $8,478,000 |
| Accumulated Depreciation | $-2,707,000 | $-2,086,000 | $-4,538,000 | $-3,984,000 |
| Gross PPE | $11,888,000 | $9,402,000 | $12,049,000 | $12,462,000 |
| Leases | $2,178,000 | $2,178,000 | $2,178,000 | $2,052,000 |
| Machinery Furniture Equipment | $2,392,000 | $2,392,000 | $4,347,000 | $4,003,000 |
| Buildings And Improvements | $7,318,000 | $4,832,000 | $5,524,000 | $6,407,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $61,904,000 | $171,301,000 | $147,561,000 | $92,012,000 |
| Finished Goods | - | $128,000 | $281,000 | $0 |
| Work In Process | - | $0 | $100,000 | $0 |
| Raw Materials | - | $103,000 | $0 | $0 |
| Other Properties | - | - | - | $6,819,000 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-67,851,000 | $-179,811,000 | $-162,367,000 | $-90,177,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-67,851,000 | $-178,780,000 | $-161,897,000 | $-88,851,000 |
| Cash Flow From Continuing Operating Activities | $-67,851,000 | $-178,780,000 | $-161,897,000 | $-88,851,000 |
| Operating Gains Losses | - | - | - | $3,000 |
| Investing Activities | ||||
| Investing Cash Flow | $113,020,000 | $-15,378,000 | $-49,943,000 | $-71,078,000 |
| Cash Flow From Continuing Investing Activities | $113,020,000 | $-15,378,000 | $-49,943,000 | $-71,078,000 |
| Capital Expenditure | - | $-1,031,000 | $-470,000 | $-1,326,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-572,000 | $-1,730,000 | $-824,000 | $-864,000 |
| Issuance Of Capital Stock | $0 | $241,322,000 | $138,823,000 | $94,205,000 |
| Financing Cash Flow | $-48,499,000 | $238,349,000 | $187,960,000 | $142,209,000 |
| Cash Flow From Continuing Financing Activities | $-48,499,000 | $238,349,000 | $187,960,000 | $142,209,000 |
| Net Preferred Stock Issuance | $0 | $241,322,000 | $0 | $0 |
| Preferred Stock Issuance | $0 | $241,322,000 | $0 | $0 |
| Net Common Stock Issuance | $-572,000 | $-1,730,000 | $137,999,000 | $93,341,000 |
| Common Stock Issuance | $0 | $0 | $138,823,000 | $94,205,000 |
| Net Other Financing Charges | - | $-1,307,000 | - | - |
| Other | ||||
| Repayment Of Debt | $-48,000,000 | $0 | $0 | - |
| Issuance Of Debt | $0 | $0 | $49,961,000 | $48,868,000 |
| Interest Paid Supplemental Data | $8,330,000 | $12,919,000 | $10,057,000 | $2,289,000 |
| End Cash Position | $63,326,000 | $66,656,000 | $22,465,000 | $46,345,000 |
| Beginning Cash Position | $66,656,000 | $22,465,000 | $46,345,000 | $64,065,000 |
| Changes In Cash | $-3,330,000 | $44,191,000 | $-23,880,000 | $-17,720,000 |
| Proceeds From Stock Option Exercised | $73,000 | $64,000 | $0 | $0 |
| Common Stock Payments | $-572,000 | $-1,730,000 | $-824,000 | $-864,000 |
| Net Issuance Payments Of Debt | $-48,000,000 | $0 | $49,961,000 | $48,868,000 |
| Net Long Term Debt Issuance | $-48,000,000 | $0 | $49,961,000 | $48,868,000 |
| Long Term Debt Payments | $-48,000,000 | $0 | $0 | - |
| Long Term Debt Issuance | $0 | $0 | $49,961,000 | $48,868,000 |
| Net Investment Purchase And Sale | $113,020,000 | $-14,347,000 | $-49,473,000 | $-69,752,000 |
| Sale Of Investment | $252,858,000 | $314,400,000 | $173,870,000 | $64,197,000 |
| Purchase Of Investment | $-139,838,000 | $-328,747,000 | $-223,343,000 | $-133,949,000 |
| Net PPE Purchase And Sale | $0 | $-1,031,000 | $-470,000 | $-1,326,000 |
| Purchase Of PPE | $0 | $-1,031,000 | $-470,000 | $-1,326,000 |
| Change In Working Capital | $-26,894,000 | $14,238,000 | $2,659,000 | $402,000 |
| Change In Other Current Assets | $757,000 | $1,152,000 | $467,000 | $656,000 |
| Change In Payables And Accrued Expense | $-30,222,000 | $14,801,000 | $6,454,000 | $76,000 |
| Change In Payable | $-30,222,000 | $14,801,000 | $6,454,000 | $76,000 |
| Change In Account Payable | $-30,222,000 | $14,801,000 | $6,454,000 | $76,000 |
| Change In Prepaid Assets | $1,532,000 | $598,000 | $-2,899,000 | $-316,000 |
| Change In Inventory | $-50,000 | $150,000 | $-381,000 | $0 |
| Change In Receivables | $1,089,000 | $-2,463,000 | $-982,000 | $-14,000 |
| Changes In Account Receivables | $1,089,000 | $-2,463,000 | $-982,000 | $-14,000 |
| Other Non Cash Items | $-42,000 | $2,657,000 | $3,286,000 | $741,000 |
| Stock Based Compensation | $12,517,000 | $13,499,000 | $14,340,000 | $11,520,000 |
| Amortization Of Securities | $-3,712,000 | $-9,305,000 | $-5,617,000 | $0 |
| Depreciation And Amortization | $621,000 | $534,000 | $554,000 | $427,000 |
| Net Income From Continuing Operations | $-50,341,000 | $-200,403,000 | $-177,119,000 | $-101,944,000 |
| Gain Loss On Sale Of PPE | - | $0 | $0 | $3,000 |
| Net Business Purchase And Sale | - | - | - | $0 |
| Sale Of Business | - | - | - | $0 |
| Sale Of PPE | - | - | - | $0 |
| Asset Impairment Charge | - | - | - | $0 |
| Gain Loss On Sale Of Business | - | - | - | $0 |
| Deferred Tax | - | - | - | - |
| Deferred Income Tax | - | - | - | - |
Fetched: 2026-06-22